Trius Therapeutics (TSRX)

Add to Watchlists Create an Alert
7.89 -0.01  -0.13%   NASDAQ May 24, 2:54PM BATS Real time Currency in USD

Trius Therapeutics SG&A Expense Quarterly:

4.504M for Dec. 31, 2012
View Full Chart

Trius Therapeutics SG&A Expense Quarterly Chart

    Trius Therapeutics Historical SG&A Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    March 31, 2013 4.504M
    Dec. 31, 2012 4.653M
    Sept. 30, 2012 4.427M
    June 30, 2012 3.311M
    March 31, 2012 3.004M
    Dec. 31, 2011 2.789M
    Sept. 30, 2011 3.731M
    June 30, 2011 2.478M
    March 31, 2011 2.342M
       
    Dec. 31, 2010 1.879M
    Sept. 30, 2010 1.296M
    June 30, 2010 1.021M
    March 31, 2010 1.21M
    Dec. 31, 2009 1.344M
    Sept. 30, 2009 0.937M
    June 30, 2009 0.857M
    March 31, 2009 0.996M
    Dec. 31, 2008 0.50M

    About SG&A Expense

    SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

    The details of how SG&A expenses are calculated vary widely from company to company, so YCharts recommends looking at the annual report (10-k) an investor is interested in dissecting this number further.
    Learn More

    Get data for

    TSRX SG&A Expense Quarterly Benchmarks

    Companies
    Genomic Health 40.57M
    Acorda Therapeutics 48.20M
    Chembio Diagnostics 1.33M

    TSRX SG&A Expense Quarterly Rankings

    Overall 55th percentile
    3575 of 8009
    Sector 51st percentile
    334 of 687 in Healthcare
    Industry 47th percentile
    34 of 65 in Diagnostics & Research

    TSRX SG&A Expense Quarterly Range, Past 5 Years

    Minimum 0.50M Dec 2008
    Maximum 4.653M Dec 2012
    Average 2.293M